Storia in 7 fonti

There’s a lack of proof to back up the peptides hype

There is promising evidence in rodent studies and, anecdotally, some patients are converts, but the core issue is the lack of clinical trials in humans.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

afr.comStai leggendo17 h fa

There’s a lack of proof to back up the peptides hype

There is promising evidence in rodent studies and, anecdotally, some patients are converts, but the core issue is the lack of clinical trials in humans.

originale

Timeline cronologica

mercoledì 22 luglio 2026·cbc.ca
U.S. FDA panel to review 7 peptides amid growing popularity | CBC News
U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry…
mercoledì 22 luglio 2026·aljazeera.com
US regulators to weigh controversial peptides backed by RFK Jr
FDA has questioned the evidence as demand surges for the compounds promoted for sleep, muscle growth, and anti-ageing.

There’s a lack of proof to back up the peptides hype

Confronto fonti

There’s a lack of proof to back up the peptides hype

Timeline cronologica

U.S. FDA panel to review 7 peptides amid growing popularity | CBC News

US regulators to weigh controversial peptides backed by RFK Jr

What's the deal with peptides? The hyped market under U.S. review

Peptide craze explodes, FDA warns ‘alarming safety concern’ as influencers fuel grey market

US regulators to weigh controversial peptides backed by RFK Jr

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

U.S. FDA panel to review 7 peptides amid growing popularity | CBC News

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

What's the deal with peptides? The hyped market under U.S. review

Which peptides could be about to become FDA-recommended?

Peptide craze explodes, FDA warns ‘alarming safety concern’ as influencers fuel grey market

There’s a lack of proof to back up the peptides hype